[go: up one dir, main page]

WO2009070609A3 - Therapeutic targeting of il-6 using sirna in neutral liposomes - Google Patents

Therapeutic targeting of il-6 using sirna in neutral liposomes Download PDF

Info

Publication number
WO2009070609A3
WO2009070609A3 PCT/US2008/084742 US2008084742W WO2009070609A3 WO 2009070609 A3 WO2009070609 A3 WO 2009070609A3 US 2008084742 W US2008084742 W US 2008084742W WO 2009070609 A3 WO2009070609 A3 WO 2009070609A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
sirna
therapeutic targeting
neutral liposomes
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/084742
Other languages
French (fr)
Other versions
WO2009070609A2 (en
Inventor
Anil Sood
Gabriel Lopez-Berestein
Guillermo Armaiz-Pena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2009070609A2 publication Critical patent/WO2009070609A2/en
Anticipated expiration legal-status Critical
Publication of WO2009070609A3 publication Critical patent/WO2009070609A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compositions that include a nucleic acid component that include a nucleic acid that inhibits the expression of a gene that encodes interleukin-6 (IL-6), and a lipid component that includes one or more phospholipids. Also disclosed are methods of treating a subject with cancer that exhibits stress-related growth involve administering to the subject a pharmaceutically effective amount of a composition that includes a nucleic acid component that includes a nucleic acid that inhibits the expression of a gene that encodes IL- 6, and a lipid component comprising one or more phospholipids.
PCT/US2008/084742 2007-11-27 2008-11-25 Therapeutic targeting of il-6 using sirna in neutral liposomes Ceased WO2009070609A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99053807P 2007-11-27 2007-11-27
US60/990,538 2007-11-27

Publications (2)

Publication Number Publication Date
WO2009070609A2 WO2009070609A2 (en) 2009-06-04
WO2009070609A3 true WO2009070609A3 (en) 2010-09-10

Family

ID=40524697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/084742 Ceased WO2009070609A2 (en) 2007-11-27 2008-11-25 Therapeutic targeting of il-6 using sirna in neutral liposomes

Country Status (1)

Country Link
WO (1) WO2009070609A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214983A1 (en) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Nebulisable liposomes and their use for pulmonary application of active substances
CN101579329B (en) * 2009-06-08 2011-11-09 沈阳亿灵医药科技有限公司 Bevantolol hydrochloride sustained release preparation
DE102009031274A1 (en) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomes for pulmonary application
CL2011000273A1 (en) * 2011-02-08 2011-06-17 Univ Pontificia Catolica Chile Use of a phosphatidic acid phosphohydrolase enzyme (pap) inhibitor or combination of inhibitors, in which the inhibitor is d (+) propranolol, and the combination is racemic mixture of propranolol od (+) propranolol together with desipramine, to prepare a Useful medicine in the treatment of cancer.
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
CN103536594A (en) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 Application of G-protein-coupled receptor antagonist in preparing medicine for treating glutamate receptor high-expression tumor
US20220364095A1 (en) * 2021-05-12 2022-11-17 Northwestern University Tunable anchor for liposomal spherical nucleic acid assembly
CN114224875B (en) * 2021-11-04 2023-08-11 中南大学湘雅医院 New use of alcohol compound and antitumor drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LANDEN CHARLES N JR ET AL: "Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.", 1 November 2007, CANCER RESEARCH 1 NOV 2007, VOL. 67, NR. 21, PAGE(S) 10389 - 10396, ISSN: 1538-7445, XP002575012 *
NILSSON MONIQUE B ET AL: "Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism.", THE JOURNAL OF BIOLOGICAL CHEMISTRY IN PRESS, no. M611539200, 23 August 2007 (2007-08-23), pages 1 - 19, XP002574048, ISSN: 0021-9258, Retrieved from the Internet <URL:http://www.jbc.org/content/early/2007/08/23/jbc.M611539200> [retrieved on 20100318], DOI: 10.1074/jbc.M611539200 *

Also Published As

Publication number Publication date
WO2009070609A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2009070609A3 (en) Therapeutic targeting of il-6 using sirna in neutral liposomes
WO2008109432A3 (en) Therapeutic targeting of interleukins using sirna in neutral liposomes
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2009149418A3 (en) Compositions for the in vivo delivery of rnai agents
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
EP2348112A3 (en) Stabilized immune modulatory RNA (SIMRA) compounds
WO2006113679A3 (en) Delivery of sirna by neutral lipid compositions
WO2004084950A3 (en) Cell targeting methods and compositions
WO2007064857A8 (en) Amphoteric liposome formulation
WO2008030818A3 (en) Novel liposome compositions
WO2006099169A3 (en) Novel liposome compositions
MX348817B (en) Methods for treating cancer and non-neoplastic conditions.
AU2009303344A8 (en) Targeting of antigen presenting cells with immunonanotherapeutics
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
NZ781029A (en) Oligonucleotide compositions and methods thereof
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2006044502A3 (en) Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
MX2009003548A (en) Lipid containing formulations.
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2009055568A3 (en) Liposomal vancomycin formulations
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2006138608A3 (en) Pharmaceutical compositions and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855077

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08855077

Country of ref document: EP

Kind code of ref document: A2